File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1478-3231.2008.01916.x
- Scopus: eid_2-s2.0-57749203825
- PMID: 19120940
- WOS: WOS:000261685700005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Management of advanced hepatocellular carcinoma in the era of targeted therapy
Title | Management of advanced hepatocellular carcinoma in the era of targeted therapy |
---|---|
Authors | |
Keywords | Advanced hepatocellular carcinoma Bevacizumab Sorafenib Targeted therapy |
Issue Date | 2009 |
Publisher | Wiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1 |
Citation | Liver International, 2009, v. 29 n. 1, p. 10-17 How to Cite? |
Abstract | Systemic chemotherapy has had a disappointing track record in the management of advanced hepatocellular carcinoma (HCC). Single-agent doxorubicin produces a response rate of 10-15%, but without any survival benefit, and combination chemotherapy has also yielded unimpressive results. With recent advances in the knowledge of hepato-carcinogenesis, there has been encouraging development in the systemic therapy of advanced HCC patients, and particularly in the targeted therapy of advanced HCC. Among the newly identified targets, exciting results have been shown in targeting the anti-angiogenic pathway and the Raf/ mitogen-activated protein kinase pathways. Bevacizumab, both as a single agent and in combination with other agents, has shown initial encouraging activity in treating advanced HCC. More recently, single-agent sorafenib, a putative multitargeted kinase inhibitor, has shown to prolong the overall survival of patients with advanced HCC in the pivotal phase III Sorafenib HCC Assessment Randomized Protocol (SHARP) and Oriental study. Currently, sorafenib is the only approved targeted therapy for patients with advanced HCC. In addition, however, promising early results have been reported for other molecular-targeted drugs including erlotinib and sunitinib. Future progress seems likely to depend on using controlled clinical trials to optimize synergistic combination treatments. © 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard. |
Persistent Identifier | http://hdl.handle.net/10722/132650 |
ISSN | 2023 Impact Factor: 6.0 2023 SCImago Journal Rankings: 2.087 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yau, T | en_HK |
dc.contributor.author | Chan, P | en_HK |
dc.contributor.author | Epstein, R | en_HK |
dc.contributor.author | Poon, RTP | en_HK |
dc.date.accessioned | 2011-03-28T09:27:24Z | - |
dc.date.available | 2011-03-28T09:27:24Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Liver International, 2009, v. 29 n. 1, p. 10-17 | en_HK |
dc.identifier.issn | 1478-3223 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/132650 | - |
dc.description.abstract | Systemic chemotherapy has had a disappointing track record in the management of advanced hepatocellular carcinoma (HCC). Single-agent doxorubicin produces a response rate of 10-15%, but without any survival benefit, and combination chemotherapy has also yielded unimpressive results. With recent advances in the knowledge of hepato-carcinogenesis, there has been encouraging development in the systemic therapy of advanced HCC patients, and particularly in the targeted therapy of advanced HCC. Among the newly identified targets, exciting results have been shown in targeting the anti-angiogenic pathway and the Raf/ mitogen-activated protein kinase pathways. Bevacizumab, both as a single agent and in combination with other agents, has shown initial encouraging activity in treating advanced HCC. More recently, single-agent sorafenib, a putative multitargeted kinase inhibitor, has shown to prolong the overall survival of patients with advanced HCC in the pivotal phase III Sorafenib HCC Assessment Randomized Protocol (SHARP) and Oriental study. Currently, sorafenib is the only approved targeted therapy for patients with advanced HCC. In addition, however, promising early results have been reported for other molecular-targeted drugs including erlotinib and sunitinib. Future progress seems likely to depend on using controlled clinical trials to optimize synergistic combination treatments. © 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard. | en_HK |
dc.language | eng | en_US |
dc.publisher | Wiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1 | en_HK |
dc.relation.ispartof | Liver International | en_HK |
dc.subject | Advanced hepatocellular carcinoma | en_HK |
dc.subject | Bevacizumab | en_HK |
dc.subject | Sorafenib | en_HK |
dc.subject | Targeted therapy | en_HK |
dc.title | Management of advanced hepatocellular carcinoma in the era of targeted therapy | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Yau, T: tyaucc@hku.hk | en_HK |
dc.identifier.email | Epstein, R: repstein@hku.hk | en_HK |
dc.identifier.email | Poon, RTP: poontp@hku.hk | en_HK |
dc.identifier.authority | Yau, T=rp01466 | en_HK |
dc.identifier.authority | Epstein, R=rp00501 | en_HK |
dc.identifier.authority | Poon, RTP=rp00446 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1478-3231.2008.01916.x | en_HK |
dc.identifier.pmid | 19120940 | - |
dc.identifier.scopus | eid_2-s2.0-57749203825 | en_HK |
dc.identifier.hkuros | 167037 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-57749203825&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 29 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 10 | en_HK |
dc.identifier.epage | 17 | en_HK |
dc.identifier.eissn | 1478-3231 | - |
dc.identifier.isi | WOS:000261685700005 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Yau, T=23391533100 | en_HK |
dc.identifier.scopusauthorid | Chan, P=7403497715 | en_HK |
dc.identifier.scopusauthorid | Epstein, R=34975074500 | en_HK |
dc.identifier.scopusauthorid | Poon, RTP=7103097223 | en_HK |
dc.identifier.citeulike | 3809924 | - |
dc.identifier.issnl | 1478-3223 | - |